Patient P-01746

Synthetic patientNBL-101 · Day 102 · 75+ · M · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Improving

Discontinuation risk

74%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −25% vs expected — Dietary Support Protocol NP-02
Day 48 Tolerance state changed — Unstable → Improving
Day 55 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 68 ME-01 recommended — Monitoring Escalation ME-01
Day 69 Patient accepted — Started ME-01 in the companion
Day 72 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 55.

Primary contributors, last 14 days

GI instability-25
Inflammatory activity-22
Nutritional resilience+10
Toxicity-8

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −25%
Monitoring Escalation ME-01Day 68
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

80%

probability of meaningful tolerance improvement

284 similar trajectories
84% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 22/100
Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Rapid metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 3.1 · butyrate capacity 22/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 53 ms
Sleep: 6.4 h
Steps: 3,767
Resting HR: 68 bpm

Daily log: GI score 40, nutritional resilience 51, adherence 47.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01458	51%	S14	GI-04	improved	44
P-01559	49%	S06	GI-04	improved	42
P-01568	49%	S14	GI-04	improved	40
P-01713	49%	S04	GI-04	improved	46
P-01356	48%	S14	GI-04	improved	42
P-01566	48%	S09	GI-04	improved	52
P-01389	46%	S14	SC-12	improved	46
P-01678	46%	S14	GI-04	improved	44
P-01365	45%	S14	SC-12	improved	49
P-01617	45%	S14	SC-12	improved	50
P-01781	45%	S14	NP-02	improved	45
P-01376	44%	S14	GI-04	improved	53